Is XOMA Corp (NASDAQ:XOMA) A Real Gem?

Posted by Samantha Donahue October 16, 2013 0 Comment 1342 views

Gevokizumab is XOMA Corp (NASDAQ:XOMA)’s lead drug-candidate that was designed to meet various therapeutic and commercial challenges that are an inherent part of IL-I inhibitors. This drug was perfect for infrequent and high-dosage treatment as it can be dosed only one a month in comparison to Ilaris which requires daily dosing. This is because it has a longer-life of around 22 days. In 2011, the company also entered into a collaboration and licensing agreement with Servier Laboratories for developing and commercializing this drug for various indications. As per this agreement, the drug is now being evaluated in a Phase3 trial dubbed EYEGUARD. The objective of this study is to determine whether gevokizumab is useful in the treatment of acute -non-infectious uveitis and in the prevention of disease-flares in patients suffering from this disease. In addition, the company has a POC in progress that will explore the safety and the efficacy of the drug for different indications. XOMA Corp (NASDAQ:XOMA) expects the Phase3 indication to be selected by the 2013 Q4.

Tuesday’s trading

In Tuesday’s trading, XOMA Corp (NASDAQ:XOMA) dropped by 5.22%. The opening price of the shares was $4.78, which was also the intraday high and dipped to a close of $4.54. Approximately 1.27 million shares were traded on Tuesday while an average volume of 1.16 million shares were traded over a 30 day period. The 52-week low of XOMA Corp (NASDAQ:XOMA) shares is $2.37 and its 52-week high is $5.54. The company has a market capitalization of $411.40 million.

About the company

XOMA Corp (NASDAQ:XOMA) is involved in discovering and developing various antibody-based therapeutics. Gevokizumab is its lead drug-candidate. This is a humanized monoclonal-allosteric modulating anti-body that is designed to inhibit pro-inflammatory-cytokine interleukin-1 beta. XOMA Corp (NASDAQ:XOMA)’s pre-clinical pipeline includes different classes of anti-bodies that either activate or sensitize XMet, the insulin-receptor in vivo.

About Samantha Donahue

Samantha Donahue is a digital fellow with GDP insider. Samantha earned a Bachelor's degree in Government from Cornell University and later his Master's degree in Journalism from Columbia University. She has also received numerous awards from the Associated Press, Society of Professional Journalists, and other media organizations for many of her exclusive stories. Samantha thrives reporting on breaking news and as a general assignments news reporter.

View all post by Samantha Donahue Visit author's website

Write Your Comment